1
|
Sirvent N, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Paillard C, Costa V, Simon P, Pluchart C, Poirée M, Minckes O, Millot F, Freycon C, Maes P, Hoyoux C, Cavé H, Rohrlich P, Bertrand Y, Benoit Y. CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951. Arch Pediatr 2021; 28:411-416. [PMID: 34034929 DOI: 10.1016/j.arcped.2021.04.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2020] [Revised: 02/25/2021] [Accepted: 04/16/2021] [Indexed: 11/25/2022]
Abstract
AIM To evaluate the prognostic significance of initial central nervous system (CNS) involvement of children with acute lymphoblastic leukemia (ALL) enrolled in the EORTC 58951 trial. PATIENTS AND METHODS From 1998 to 2008, 1930 ALL patients were included in the randomized EORTC 58951 trial. Overall treatment intensity was adjusted according to known prognostic factors including the level of minimal residual disease after induction treatment. CNS-directed therapy comprised four to 11 courses of i.v. methotrexate (5g/m2), and 10 to 19 intrathecal chemotherapy injections, depending on risk group and CNS status. Cranial irradiation was omitted for all patients. RESULTS The overall 8-year event-free survival (EFS) and overall survival (OS) rates were 81.3% and 88.1%, respectively. In the CNS-1, TPL+, CNS-2, and CNS-3 groups, the 8-year EFS rates were 82.1%, 77.1%, 78.3%, and 57.4%, respectively. Multivariable analysis indicated that initial CNS-3 status, but not CNS-2 or TLP+, was an independent adverse predictor of outcome. The 8-year incidence of isolated CNS relapse was 1.7% and of isolated or combined CNS relapse it was 3.7%. NCI high-risk group, male sex, CNS-2 and CNS-3 status were independent predictors for a higher incidence of any CNS relapse. CONCLUSIONS CNS-3 status remains associated with poor prognosis and requires intensification of both systemic and CNS-directed therapy. This trial was registered at https://clinicaltrials.gov/under/NCT00003728.
Collapse
Affiliation(s)
- N Sirvent
- Department of Pediatric Hematology-Oncology, CHU, Montpellier, France; University Montpellier, Montpellier, France.
| | - S Suciu
- EORTC Headquarters, Brussels, Belgium
| | - B De Moerloose
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Ghent, Belgium
| | - A Ferster
- Department of Pediatric Hematology-Oncology, Children's University Hospital Queen Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - F Mazingue
- Department of Pediatric Hematology-Oncology, CHRU, Lille, France
| | - G Plat
- Department of Pediatric Hematology-Oncology, CHU-Hôpital Purpan, Toulouse, France
| | - K Yakouben
- Department of Pediatric Hematology, Robert-Debré Hospital, AP-HP, Paris, France
| | - A Uyttebroeck
- Department of Pediatric Hematology-Oncology, University Hospital Gasthuisberg, Leuven, Belgium
| | - C Paillard
- Department of Pediatric Hematology-Oncology, University Hospital Hautepierre, Strasbourg, France
| | - V Costa
- Department of Pediatrics, Portuguese Oncology Institute, Porto, Portugal
| | - P Simon
- Pediatric Hematology Unit, CHU Jean-Minjoz Hospital, Besançon, France
| | - C Pluchart
- Department of Pediatric Hematology-Oncology, American Memorial Hospital, Reims, France
| | - M Poirée
- Department of Pediatric Hematology-Oncology, CHU Nice, Nice, France
| | - O Minckes
- Department of Pediatric Hematology-Oncology, CHU, Caen, France
| | - F Millot
- Pediatric Oncology Unit, University Hospital, Poitiers, France
| | - C Freycon
- Department of Pediatric Oncology, University Hospital, Grenoble, France
| | - P Maes
- Department of Pediatrics, University Hospital Antwerp, Antwerp, Belgium
| | - C Hoyoux
- Department of Pediatrics, CHR de la Citadelle, Liège, Belgium
| | - H Cavé
- Department of Genetics, Assistance publique-Hôpitaux de Paris (AP-HP), Robert-Debré Hospital, Paris, France; INSERM UMR 1131, University Institute of Hematology, University Paris-Diderot, Paris Sorbonne Cité, Paris, France
| | - P Rohrlich
- Department of Pediatric Hematology-Oncology, CHU Nice, Nice, France
| | - Y Bertrand
- Institute of Pediatric Hematology and Oncology (IHOP), Hospices Civils de Lyon, University Lyon 1, Lyon, France
| | - Y Benoit
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Ghent, Belgium
| | | |
Collapse
|
2
|
Piette C, Suciu S, Clappier E, Bertrand Y, Drunat S, Girard S, Yakouben K, Plat G, Dastugue N, Mazingue F, Grardel N, van Roy N, Uyttebroeck A, Costa V, Minckes O, Sirvent N, Simon P, Lutz P, Ferster A, Pluchart C, Poirée M, Freycon C, Dresse MF, Millot F, Chantrain C, van der Werff Ten Bosch J, Norga K, Gilotay C, Rohrlich PS, Benoit Y, Cavé H. Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials. Leukemia 2018; 32:244-248. [PMID: 29064485 DOI: 10.1038/leu.2017.289] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C Piette
- University Department of Pediatrics, Pediatric Onco-Hematology, CHR Citadelle, Liège, Belgium
| | - S Suciu
- EORTC Headquarters, Brussels, Belgium
| | - E Clappier
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
- Institut Universitaire d'Hématologie, Université Paris Diderot, Paris-Sorbonne-Cité, Paris, France
| | - Y Bertrand
- Department of Pediatric Hematology, IHOP, Hospices Civils de Lyon and Claude Bernard Lyon University, Lyon, France
| | - S Drunat
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - S Girard
- Laboratory of Hematology, East Lyon University Hospital, Hospices Civils de Lyon, Lyon, France
| | - K Yakouben
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Immuno-Hématologie pédiatrique, Paris, France
| | - G Plat
- Department of Pediatric Onco-Hematology, Purpan University Hospital, Toulouse, France
| | - N Dastugue
- Department of Pediatric Onco-Hematology, Purpan University Hospital, Toulouse, France
| | - F Mazingue
- Department of Pediatric Hematology-Oncology, Lille University Hospital, Lille, France
| | - N Grardel
- Department of Pediatric Hematology-Oncology, Lille University Hospital, Lille, France
| | - N van Roy
- Center for Medical Genetics, Ghent University, Ghent, Belgium
| | - A Uyttebroeck
- Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium
| | - V Costa
- Department of Pediatrics, Portuguese Oncology Institute, Porto, Portugal
| | - O Minckes
- Department of Pediatric Onco-Hematology, Caen University Hospital, Caen, France
| | - N Sirvent
- Department of Pediatric Onco-Hematology, Montpellier University Hospital, Montpellier, France
| | - P Simon
- Department of Pediatric Onco-Hematology, Besançon University Hospital, Besançon, France
| | - P Lutz
- Department of Hematology, Hautepierre University Hospital, Strasbourg, France
| | - A Ferster
- Department of Pediatric Onco-Hematology, Hôpital Universitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium
| | - C Pluchart
- Department of Pediatric Onco-Hematology, Reims University Hospital, Reims, France
| | - M Poirée
- Department of Pediatric Onco-Hematology, Nice University Hospital, Nice, France
| | - C Freycon
- Department of Pediatric Onco-Hematology, Grenoble University Hospital, Grenoble, France
| | - M-F Dresse
- University Department of Pediatrics, Pediatric Onco-Hematology, CHR Citadelle, Liège, Belgium
| | - F Millot
- Department of Pediatric Onco-Hematology, Poitiers University Hospital, Poitiers, France
| | - C Chantrain
- Department of Pediatrics, Clinique de l'Espérance, CHC, Liège, Belgium
| | | | - K Norga
- Pediatric Onco-Hematology Unit, Antwerp University Hospital, Antwerp, Belgium
| | - C Gilotay
- EORTC Headquarters, Brussels, Belgium
| | - P-S Rohrlich
- Department of Pediatric Onco-Hematology, Nice University Hospital, Nice, France
| | - Y Benoit
- Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium
| | - H Cavé
- Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
- Institut Universitaire d'Hématologie, Université Paris Diderot, Paris-Sorbonne-Cité, Paris, France
| |
Collapse
|
3
|
Sirvent A, Auquier P, Oudin C, Bertrand Y, Bohrer S, Chastagner P, Poirée M, Kanold J, Thouvenin S, Perel Y, Plantaz D, Tabone MD, Yakouben K, Gandemer V, Lutz P, Sirvent N, Vercasson C, Berbis J, Chambost H, Leverger G, Baruchel A, Michel G. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study. Bone Marrow Transplant 2016; 52:80-87. [PMID: 27595286 DOI: 10.1038/bmt.2016.205] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 06/26/2016] [Accepted: 06/30/2016] [Indexed: 12/16/2022]
Abstract
Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l'Enfant et de l'Adolescent cohort) to determine the prevalence and risk factors of IO in 384 acute leukemia survivors transplanted during childhood. Prevalence of IO (ferritin level ⩾350 ng/mL) was 42.2% (95%CI 37.2-47.2%). Factors significantly associated with IO were: 1) in univariate analysis: older age at transplant (P<0.001), allogeneic versus autologous transplantation (P<0.001), radiation-based preparative regimen (P=0.035) and recent period of transplantation (P<0.001); 2) in multivariate analysis: older age at transplant in quartiles (Odds Ratio (OR)=7.64, 95% CI: 3.73-15.64 for age >12.7 years and OR=5.36, 95% CI: 2.63-10.95 for age from 8.2 to 12.7 years compared to age < 4.7 years), acute myeloid leukemia (OR=3.23, 95% CI: 1.47-7.13), allogeneic graft (OR=4.34, 95% CI: 2.07-9.12 for alternative donors and OR=2.53, 95% CI: 1.2-5.33 for siblings, compared to autologous graft) and radiation-based conditioning regimen (OR=2.45, 95% CI: 1.09-5.53). Graft-versus-host disease was an additional risk factor for allogeneic graft recipients. In conclusion, IO is a frequent complication in pediatric long-term survivors after transplantation for acute leukemia, more frequently observed in older children, those transplanted from alternative donors or with graft-versus-host disease.
Collapse
Affiliation(s)
- A Sirvent
- Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France
| | - P Auquier
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
| | - C Oudin
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.,Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| | - Y Bertrand
- Department of Pediatric Hematology and Oncology, University Hospital, Lyon, France
| | - S Bohrer
- Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France
| | - P Chastagner
- Department of Pediatric Hematology and Oncology, Hôpital d'Enfants de Brabois, Vandoeuvre Les Nancy, France
| | - M Poirée
- Department of Pediatric Hematology and Oncology, University Hospital L'Archet, Nice, France
| | - J Kanold
- Department of Pediatric Hematology and Oncology, University Hospital, Clermont-Ferrand, France
| | - S Thouvenin
- Department of Pediatric Hematology and Oncology, University Hospital, Saint Etienne, France
| | - Y Perel
- Department of Pediatric Hematology and Oncology, University Hospital, Bordeaux, France
| | - D Plantaz
- Department of Pediatric Hematology and Oncology, University Hospital, Grenoble, France
| | - M-D Tabone
- Department of Pediatric Hematology and Oncology, Trousseau Hospital, Paris, France
| | - K Yakouben
- Department of Pediatric Hematology- Immunology, Robert Debré Hospital, and Paris Diderot University, Sorbonne Paris-Cité, Paris, France
| | - V Gandemer
- Department of Pediatric Hematology and Oncology, University Hospital, Rennes, France
| | - P Lutz
- Department of Pediatric Hematology-oncology, Hospital University, Strasbourg, France
| | - N Sirvent
- Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France
| | - C Vercasson
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
| | - J Berbis
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
| | - H Chambost
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| | - G Leverger
- Department of Pediatric Hematology and Oncology, Trousseau Hospital, Paris, France
| | - A Baruchel
- Department of Pediatric Hematology- Immunology, Robert Debré Hospital, and Paris Diderot University, Sorbonne Paris-Cité, Paris, France
| | - G Michel
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.,Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| |
Collapse
|
4
|
Sauret A, Rabiau N, Rochette E, Grèze V, Halle P, Ouachée M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Curtillet C, Poirée M, Kanold J, Merlin E. Shortened apheresis-based extra-corporeal photochemotherapy for acute refractory GVHD in children: a prospective study. Bone Marrow Transplant 2016; 51:866-8. [DOI: 10.1038/bmt.2016.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
5
|
Jouannelle C, Giansily-Blaizot M, Monpoux F, Casagrande F, Poirée M, Bérard E. Spontaneous umbilical cord haematoma and congenital factor VII deficiency. Haemophilia 2011; 18:e24-5. [PMID: 21967451 DOI: 10.1111/j.1365-2516.2011.02664.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Tabone MD, Berger C, Pacquement H, Poirée M, Plantaz D, Michel G. État de santé et qualité de vie à long terme après guérison d’un cancer traité durant l’enfance. ONCOLOGIE 2011. [DOI: 10.1007/s10269-011-2002-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Breaud J, Thouret M, Boyer C, Bensaid R, Lee J, Kurzenne J, Poirée M, Soler C. P283 - Une hématurie macrocopique persistante révélant.... une appendicite pelvienne abcédée évoluant depuis 2 mois. À propos d’un cas. Arch Pediatr 2010. [DOI: 10.1016/s0929-693x(10)70681-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Gari-Toussaint M, Poirée M, Mouroux J, Novelas S, Butori C, Gantier JC. Infection pulmonaire à Cunninghamella bertholletiae chez une jeune patiente leucémique. J Mycol Med 2006. [DOI: 10.1016/j.mycmed.2006.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Vaillaud JC, Manassero J, Poirée M. [Intolerance of beta-lactoglobulin with anaphylactic shock ameliorated by desensitization]. Pediatrie 1969; 24:585-95. [PMID: 5408862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|